As the antibody–drug conjugate (ADC) landscape rapidly evolves, the industry is moving beyond traditional cytotoxic payloads and antibody-first development strategies toward more integrated, precision-engineered therapeutics. In a BioPharma Boa... Read more
In this BioPharma Boardroom interview, Steven Quay, Founder and CEO of Atossa Therapeutics, outlines the scientific rationale behind developing (Z)-endoxifen as a direct therapeutic rather than relying on the metabolic activation of Tamoxifen. He exp... Read more
As artificial intelligence becomes increasingly embedded in formulation science and early clinical planning, the industry faces a dual challenge: accelerating timelines while safeguarding scientific rigor, patient safety, and regulatory trust. In thi... Read more
Under the leadership of Joel Latham, Incannex Healthcare is advancing a differentiated pipeline of cannabinoid- and psychedelic-based therapeutics targeting significant unmet needs in sleep disorders, inflammatory disease, and anxiety... Read more
Highly potent drugs now account for over 30% of the global pipeline, with more than 1,000 molecules in development — Axplora’s investments in HPAPI capacity help customers bring these complex therapies to market faster $60 ... Read more
Expands Agilent’s pathology portfolio through addition of highly complementary antibody, reagent and instrument business with annual double-digit revenue and profit growth since 2021 Expected to be accretive to Agilent’s top-line gro... Read more
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased. Union emphasizes this is a fight against structural corporate governance issues, citing... Read more
Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters Marks Samsung Biologics’ geographical diversification and establishes its first U.S. manufacturing presence, expanding regional client support P... Read more
© 2026 Biopharma Boardroom. All Rights Reserved.
